Dianthus Therapeutics, Inc.
DNTH
$115.96
$6.365.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 294.30% | -60.19% | -78.58% | -81.77% | -89.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 294.30% | -60.19% | -78.58% | -81.77% | -89.64% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 294.30% | -60.19% | -78.58% | -81.77% | -89.64% |
| SG&A Expenses | 52.86% | 69.38% | 46.00% | 25.27% | 47.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.23% | 36.85% | 110.05% | 26.85% | 45.93% |
| Operating Income | -76.03% | -40.26% | -117.89% | -34.74% | -57.30% |
| Income Before Tax | -58.76% | -38.37% | -126.55% | -46.04% | -79.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.76% | -38.37% | -126.55% | -46.04% | -79.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.76% | -38.37% | -126.55% | -46.04% | -79.64% |
| EBIT | -76.03% | -40.26% | -117.89% | -34.74% | -57.30% |
| EBITDA | -76.08% | -40.27% | -117.98% | -34.76% | -57.33% |
| EPS Basic | -1.51% | -3.10% | -76.48% | -32.30% | -71.64% |
| Normalized Basic EPS | -9.24% | 0.95% | -64.60% | -27.98% | -73.63% |
| EPS Diluted | -1.51% | -3.10% | -76.48% | -32.30% | -71.64% |
| Normalized Diluted EPS | -9.24% | 0.95% | -64.60% | -27.98% | -73.63% |
| Average Basic Shares Outstanding | 56.41% | 34.20% | 28.37% | 10.39% | 4.66% |
| Average Diluted Shares Outstanding | 56.41% | 34.20% | 28.37% | 10.39% | 4.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |